FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1819-1834 October 27, 2005 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Recurrent episodes of major depression, which is a common and serious illness, are called major depressive disorder; depressive episodes that occur in conjunction with manic episodes are called bipolar disorder. Major depressive disorder accounts for 4.4 percent of the total overall global disease burden, a contribution similar to that of ischemic heart disease or diarrheal diseases.¹ The prevalence of major depressive disorder in the United States is 5.4 to 8.9 percent² and of bipolar disorder, 1.7 to 3.7 percent.³ Major depression affects 5 to 13 percent of medical outpatients,⁴ yet is often undiagnosed and untreated.^5,6 Moreover, it is often undertreated . . . [Full Text of this Article]

Pathophysiological Features of Depression

Diagnosis of a Major Depressive Episode

Antidepressant Medications

SSRIs

Norepinephrine-Reuptake Inhibitors

Dual-Action Antidepressants

MAOIs

Other Antidepressants and New Therapies

Augmenting and Adjunctive Medications

Mood Stabilizers

Antipsychotic Agents

Overall Therapeutic Strategy

Acute Phase

Monitoring Treatment Response

Continuation Phase

Discontinuation of Treatment

Maintenance Phase

Nonpharmacologic Therapies

ECT

Psychotherapy

Special Patient Populations

Patients with Bipolar Disorder

Children and Adolescents

Pregnant Women

Summary

Source Information

From the Department of Neuroscience, New York State Psychiatric Institute–Columbia University College of Physicians and Surgeons, New York.

Address reprint requests to Dr. Mann at the Department of Neuroscience, New York State Psychiatric Institute, 1051 Riverside Dr., Box 42, New York, NY 10032, or at jjm@columbia.edu.

Related Letters:

Medical Management of Depression
Grajower M. M., Malani A. K., Ammar H., Kemper K. J., Mann J. J.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:646-648, Feb 9, 2006. Correspondence

This article has been cited by other articles:

• Gardarsdottir, H., Egberts, T. C., Stolker, J. J., Heerdink, E. R. (2009). Duration of Antidepressant Drug Treatment and Its Influence on Risk of Relapse/Recurrence: Immortal and Neglected Time Bias. Am J Epidemiol 170: 280-285 [Abstract] [Full Text]  
• Dolder, C. R, Nelson, M., Snider, M. (2008). Agomelatine Treatment of Major Depressive Disorder. The Annals of Pharmacotherapy 42: 1822-1831 [Abstract] [Full Text]  
• Hunter, T. S. (2008). L-methylfolate in the Therapeutic Management of Major Depressive Disorder. Journal of Pharmacy Practice 21: 278-286 [Abstract]  
• Belmaker, R.H., Agam, G. (2008). Major Depressive Disorder. NEJM 358: 55-68 [Full Text]  
• Cukor, D., Cohen, S. D., Peterson, R. A., Kimmel, P. L. (2007). Psychosocial Aspects of Chronic Disease: ESRD as a Paradigmatic Illness. J. Am. Soc. Nephrol. 18: 3042-3055 [Abstract] [Full Text]  
• Cohen, S. D., Norris, L., Acquaviva, K., Peterson, R. A., Kimmel, P. L. (2007). Screening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal Disease. CJASN 2: 1332-1342 [Abstract] [Full Text]  
• Dietz, P. M., Williams, S. B., Callaghan, W. M., Bachman, D. J., Whitlock, E. P., Hornbrook, M. C. (2007). Clinically Identified Maternal Depression Before, During, and After Pregnancies Ending in Live Births. Am. J. Psychiatry 164: 1515-1520 [Abstract] [Full Text]  
• Badaracco, M. A. (2007). Keeping Our Depressed Patients in the Right Treatment Long Enough for Them to Get Better: Some Hopeful Findings. Am. J. Psychiatry 164: 1136-1139 [Full Text]  
• Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., Friedman, J. M., the National Birth Defects Prevention Study, (2007). Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects. NEJM 356: 2684-2692 [Abstract] [Full Text]  
• Cukor, D., Coplan, J., Brown, C., Friedman, S., Cromwell-Smith, A., Peterson, R. A., Kimmel, P. L. (2007). Depression and Anxiety in Urban Hemodialysis Patients. CJASN 2: 484-490 [Abstract] [Full Text]  
• Raymond, C. B., Morgan, S. G., Caetano, P. A. (2007). Antidepressant Utilization in British Columbia From 1996 to 2004: Increasing Prevalence but Not Incidence. Psychiatr. Serv. 58: 79-84 [Abstract] [Full Text]  
• Carod-Artal, F. J. (2007). Are Mood Disorders a Stroke Risk Factor?. Stroke 38: 1-3 [Full Text]  
• Ehret, M. J. (2006). Pharmacogenomics of Antidepressant Medications. Journal of Pharmacy Practice 19: 342-352 [Abstract]  
• Ehret, M. J., Chavez, B. (2006). A Review of the STAR*D Trial. Journal of Pharmacy Practice 19: 353-360 [Abstract]  
• MOREIRA-ALMEIDA, A., PIETROBON, R. (2006). Does Olanzapine Have Any Antidepressant Effect?. Am. J. Psychiatry 163: 1838-1839 [Full Text]  
• Whooley, M. A. (2006). Depression and cardiovascular disease: healing the broken-hearted.. JAMA 295: 2874-2881 [Abstract] [Full Text]  
• Reifler, B. V. (2006). Play it again, Sam--depression is recurring.. NEJM 354: 1189-1190 [Full Text]  
• Mills, J. L. (2006). Depressing Observations on the Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy. NEJM 354: 636-638 [Full Text]  
• Grajower, M. M., Malani, A. K., Ammar, H., Kemper, K. J., Mann, J. J. (2006). Medical management of depression.. NEJM 354: 646-648 [Full Text]  
• (2005). Reviews of Note. JWatch Psychiatry 2005: 2-2 [Full Text]